drugset
drugset / Trial / NCT07645534

Safety and Pharmacokinetics of Ingavirin Forte, Capsules, 90 mg + 20 mg (Valenta Pharm JSC, Russia) Compared With Ingavirin, Capsules, 90 mg, Under Fasting and Fed Conditions.

NCT07645534 ↗

Phase 1 Recruiting 36 enrolled Valenta Pharm JSC
RandomizedCrossoverOpen-labelOther

Summary

This study aims to evaluate the safety and pharmacokinetic profile of the active ingredients Ingavirin forte, capsules, 90 mg + 20 mg (Valenta Pharm JSC, Russia) relative to single-entity Drug Ingavirin, capsules, 90 mg following administration under fasting and fed conditions.

Timeline

Start
2025-07-11
Primary completion
2027-12-31
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject N,N'-bis-[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl] diamide of malonic acid Unknown 20 mg —
Subject imidazolylethanamide of pentanedioic acid Unknown 90 mg —

Indications

influenza